Table 6 Sensitivity analysis
Model parameters | Range of values | ICER (RM) |
|---|---|---|
Dose regimen | 3-4 doses | 25,576 - 35,196 |
Herd effects | Â | Â |
Lower 95% bound on herd effects | Â | Â |
   Age 20-30 | 23% | 37,648 |
   Age 40-64 | 1% |  |
   Age ≥ 65 | 11% |  |
Higher herd effects | Â | Â |
   Age 20-30 | 41% | 31,886 |
   Age 40-64 | 20% |  |
   Age ≥ 65 | 31% |  |
Discounting of costs (benefits not discounted) | 3% | 33,140 |
Vaccine serotype coverage | 61.7-71.7% | 34,208 - 36,242 |
% cohort vaccinated | 80-100% | 31,711 - 32,751 |
Vaccine efficacy | Â | Â |
IPD | 82.7% to 99.9% | 34,377 - 40,896 |
Pneumonia | -1.5% to 11% | 34,802 - 35,788 |
Otitis Media | 4.1% to 9.7% | 35,184 - 35,209 |
Disease incidence | Â | Â |
Meningitis | Â | 26,703 - 41.777 |
Bacteraemia | 50% to 200% of base case | 21,629 - 50,437 |
Pneumonia | Â | 34,723 - 35,433 |
Otitis Media | Â | 35,166 - 35,212 |